|Trade names||Sovaldi, Soforal, others|
|Metabolism||Quickly activated to triphosphate (CatA/CES1, HIST1, phosphorylation)|
|Biological half-life||0.4 hrs (sofosbuvir)
27 hrs (inactive metabolite GS-331007)
|Excretion||80% urine, 14% feces (mostly as GS-331007)|
|Chemical and physical data|
|Molar mass||529.453 g/mol|
|3D model (JSmol)|
Sofosbuvir, sold under the brand name Sovaldi among others, is a medication used for the treatment of hepatitis C. It is only recommended with some combination of ribavirin, peginterferon-alfa, simeprevir, ledipasvir, daclatasvir, or velpatasvir. Cure rates are 30 to 97% depending on the type of hepatitis C virus involved. Safety during pregnancy is unclear; while, some of the medications used in combination may result in harm to the baby. It is taken by mouth.
Common side effects include feeling tired, headache, nausea, and trouble sleeping. Side effects are generally more common in interferon-containing regimens.:7 Sofosbuvir may reactivate hepatitis B in those who have been previously infected. In combination with ledipasvir, daclatasvir or simeprevir it is not recommended with amiodarone due to the risk of an abnormally slow heartbeat. Sofosbuvir is in the nucleotide analog family of medication and works by blocking the hepatitis C NS5B protein.
Sofosbuvir was discovered in 2007 and approved for medical use in the United States in 2013. It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system. As of 2016 a 12-week course of treatment costs about $84,000 in the United States, $53,000 in the United Kingdom, $45,000 in Canada, and $483 in India. Over 60,000 people were treated with sofosbuvir in its first 30 weeks being sold in the United States.
- 1 Medical uses
- 2 Contraindications
- 3 Side effects
- 4 Interactions
- 5 Pharmacology
- 6 Chemistry
- 7 History
- 8 Society and culture
- 9 Research
- 10 See also
- 11 References
- 12 External links
Initial HCV treatment
In 2016, the American Association for the Study of Liver Diseases and the Infectious Diseases Society of America jointly published a recommendation for the management of hepatitis C. In this recommendation, sofosbuvir used in combination with other drugs is part of all first-line treatments for HCV genotypes 1, 2, 3, 4, 5, and 6, and is also part of some second-line treatments. Sofosbuvir in combination with velpatasvir is recommended for all genetypes with a cure rate greater than 90%, and close to 100% in most cases. The duration of treatment is typically 12 weeks.
Sofosbuvir is also used with other medications and longer treatment durations, depending on specific circumstances, genotype and cost-effectiveness–based perspective. For example, for the treatment of genotypes 1, 4, 5, and 6 hepatitis C infections, sofosbuvir can be used in combination with the viral NS5A inhibitor ledipasvir. In genotype 2 and 3 HCV infections, sofosbuvir can be used in combination with daclatasvir. For the treatment of cases with cirrhosis or liver transplant patients, weight-based ribavirin is sometimes added. Peginterferon with or without sofosbuvir is no longer recommended in an initial HCV treatment.
Compared to previous treatments, sofosbuvir-based regimens provide a higher cure rate, fewer side effects, and a two- to four-fold reduced duration of therapy. Sofosbuvir allows most people to be treated successfully without the use of peginterferon, an injectable drug with severe side effects that is a key component of older drug combinations for the treatment of hepatitis C virus.
Prior failed treatment
For people who have experienced treatment failure with some form of combination therapy for hepatitis C infection, one of the next possible steps would be retreatment with sofosbuvir and either ledipasvir or daclatasvir, with or without weight-based ribavirin. What genotype and particular combination therapy a person was on when the initial treatment failed are also taken into consideration when deciding on which combination to use next. The duration of retreatment can also range from 12 weeks to 24 weeks depending on factors such as which medications are used for the retreatment, whether the person has liver cirrhosis or not, and whether the liver damage is classified as compensated cirrhosis or decompensated cirrhosis.
Pregnancy and breastfeeding
Sofosbuvir alone has been assigned a Pregnancy Category B by the FDA (meaning that it there are no adequate and well-controlled studies in pregnant women but animal reproduction studies have not demonstrated a risk to the fetus and, or that adverse effects have been seen in animal studies, but adequate and well-controlled studies in pregnant women have not, in any trimester). However, ribavirin, a medication that is often given together with sofosbuvir to treat hepatitis C, is assigned a Pregnancy Category X (contraindicated in pregnancy) by the FDA. Pregnant women with hepatitis C who take ribavirin have shown some cases of birth defects and death in their fetus. It is recommended that sofosbuvir/ribarivin combinations be avoided in pregnant females and their male sexual partners in order to reduce harmful fetal defects caused by ribavirin. Females who could potentially become pregnant should undergo a pregnancy test 2 months prior to starting the sofosbuvir/ribavirin/peginterferon combination treatment, monthly throughout the duration of the treatment, and 6 months post-treatment to reduce the risk of fetal harm in case of accidental pregnancy.
It is unknown whether sofosbuvir and ribavirin pass into breastmilk; therefore, it is recommended that the mother does not breastfeed during treatment with sofosbuvir alone or in combination with ribavirin.
There are no specific contraindications for sofosbuvir when used alone. However, when used in combination with ribavirin or peginterferon alfa/ribavirin, or others, the contraindications applicable to these agents are applied.
Sofosbuvir used alone and in combination with other drugs such as ribavirin with or without a peginterferon has a good safety profile. Common side effects are fatigue, headache, nausea, rash, irritability, dizziness, back pain, and anemia. Most side effects are significantly more common in interferon-containing regimens as compared to interferon-free ones. For example, fatigue and headache are nearly cut in half, influenza-like symptoms are reduced to 3–6% as compared to 16–18%, and neutropenia is almost absent in interferon-free treatment.:7
Sofosbuvir may reactivate hepatitis B in those who have been previously infected.
Sofosbuvir is a substrate of P-glycoprotein, a transporter protein that pumps drugs and other substances from intestinal epithelium cells back into the gut. Therefore, inducers of intestinal P-glycoprotein, such as rifampicin and St. John's wort, could reduce the absorption of sofosbuvir.
In addition, coadministration of sofosbuvir with anticonvulsants (carbamazepine, phenytoin, phenobarbital, oxcarbazepine), antimycobacterials (rifampin, rifabutin, rifapentine), and the HIV protease inhibitor tipranavir and ritonavir is expected to decrease sofosbuvir concentration. Thus, coadministration is not recommended.
The interaction between sofosbuvir and a number of other drugs, such as ciclosporin, darunavir/ritonavir, efavirenz, emtricitabine, methadone, raltegravir, rilpivirine, tacrolimus, or tenofovir disoproxil, were evaluated in clinical trials and no dose adjustment is needed for any of these drugs.
Mechanism of action
Sofosbuvir is a prodrug. It is metabolized to the active antiviral agent GS-461203 (2'-deoxy-2'-α-fluoro-β-C-methyluridine-5'-triphosphate). GS-461203 serves as a defective substrate for the NS5B protein, which is the viral RNA polymerase, thus acts as an inhibitor of viral RNA synthesis. Although sofosbuvir has a 3' hydroxyl group to act as a nucleophile for an incoming NTP, a similar nucleotide analogue, 2'-deoxy-2'-α-fluoro-β-C-methylcytidine, is proposed to act as a chain terminator because the 2' methyl group of the nucleotide analogue causes a steric clash with an incoming NTP. Sobosbuvir would act in a similar way.
Sofosbuvir is only administered orally. The peak concentration after oral administration is 0.5–2 hours post-dose, regardless of initial dose. Peak plasma concentration of the main circulating metabolite GS-331077 occurs 2–4 hours post-dose. GS-331077 is the pharmacologically inactive nucleoside.
Sofosbuvir is activated in the liver to the triphosphate GS-461203 by hydrolysis of the carboxylate ester by either of the enzymes cathepsin A or carboxylesterase 1, followed by cleaving of the phosphoramidate by the enzyme histidine triad nucleotide-binding protein 1 (HINT1), and subsequent repeated phosphorylation. Dephosphorylation creates the inactive metabolite GS-331077. The half life of sofosbuvir is 0.4 hours, and the half life of GS-331007 is 27 hours.
Following a single 400 mg oral dose of sofosbuvir, 80% is excreted in urine, 14% in feces, and 2.5% in expired air recovery. However, of the urine recovery 78% was the metabolite (GS-331007) and 3.5% was sofosbuvir.
Prior to the discovery of sofosbuvir, a variety of nucleoside analogs had been examined as antihepatitis C treatments, but these exhibited relatively low potency. This low potency arises in part because the enzymatic addition of the first of the three phosphate groups of the triphosphate is slow. The design of sofosbuvir, based on the ProTide approach, avoids this slow step by building the first phosphate group into the structure of the drug during synthesis. Additional groups are attached to the phosphorus to temporarily mask the two negative charges of the phosphate group, thereby facilitating entry of the drug into the infected cell. The NS5B protein is a RNA-dependent RNA polymerase critical for the viral reproduction cycle.
Sofosbuvir was discovered by Michael Sofia, a scientist at Pharmasset, in 2007 and the drug was first tested in people in 2010 and in 2011 Gilead Sciences bought Pharmasset for about $11 billion. Gilead submitted the New Drug Application for sofosbuvir in combination with ribavirin in April 2013, and in October 2013 it received the FDA's Breakthrough Therapy Designation. In December 2013, the FDA approved sofosbuvir in combination with ribavirin for oral dual therapy of HCV genotypes 2 and 3, and for triple therapy with injected pegylated interferon (pegIFN) and RBV for treatment-naive people with HCV genotypes 1 and 4. Two months before, the FDA had approved another drug for HepC, simeprevir.
Prior to the availability of sofosbuvir, hepatitis C treatments involved 6 to 12 months treatment with an interferon-based regimen that provided cure rates of 70% or less and was associated with severe side effects including anemia, depression, severe rash, nausea, diarrhea, and fatigue. As sofosbuvir clinical development progressed, physicians began to "warehouse" people in anticipation of its availability. Sofosbuvir's U.S. launch was the fastest of any new drug in history. Over 60,000 people were treated with sofosbuvir in its first 30 weeks on the U.S. market, about 5% of the U.S. infected population.
Society and culture
Sofosbuvir is on the World Health Organization's List of Essential Medicines, the most important medications needed in a basic health system.
The price of sofosbuvir, quoted in various media sources as $84,000 to $168,000 for a course of treatment in the U.S., £35,000 in the UK for 12 weeks has engendered considerable controversy. However, sofosbuvir is significantly more affordable in Japan and South Korea at approximately $300 and $5900 respectively for a 12-week treatment, with each government covering 99% and 70% of the cost respectively. In 2014, Gilead announced that it would work with generic manufacturers in 91 developing countries to produce and sell sofosbuvir, and that it would sell a name brand version of the product in India for approximately $300 per course of treatment; it had signed agreements with generic manufacturers by September 2015.
As of 2016 for a course of treatment it costs about $84,000 in the United States. In 2014 the list price of 12 weeks combination treatment with a sofosbuvir-based regimen sosbuvir ranges from US$84,000 to $94,000. In April 2014 U.S. House Democrats Henry Waxman, Frank Pallone Jr., and Diana DeGette wrote Gilead Sciences Inc. questioning the $84,000 price for sofosbuvir. They specifically asked Gilead CEO John Martin to "explain how the drug was priced, what discounts are being made available to low-income patients and government health programs, and the potential impact to public health by insurers blocking or delaying access to the medicine because of its cost." Sofosbuvir is cited as an example of how specialty drugs present both benefits and challenges.
Sofosbuvir also is an excellent example of both the benefit and the challenge of specialty medications. On one hand, this agent offers up to a 95% response rate as part of an interferon-free treatment regimen for hepatitis C. Generally speaking, it is more effective and better tolerated than alternative treatments. Unfortunately, the current per pill cost—$1,000—results in an $84,000 treatment course, creating barriers to therapy for many. Patients, providers, and payors alike have expressed outrage, and the debate has even drawn the attention of the US Congress. Despite these concerns, sofosbuvir rapidly has become a top seller in the United States…
In February 2015 Gilead announced that due in part to negotiated discounts with pharmacy benefit managers and legally mandated discounts to government payers, the average discount to list price in 2014 was 22%. The company estimated that the average discount in 2015 would be 46%. According to the California Technology Assessment Forum, a panel of academic pharmacoeconomic experts, representatives of managed care organizations, and advocates for people with hepatitis, a 46% discount would bring the average price of treatment to about $40,000, at which price sofosbuvir-based treatment regimens represent a "high value" for people and healthcare systems.
Because of sofosbuvir's high price in the United States, by 2017, some states—such as Louisiana—were withholding the medicine from Medicaid patients with hepatitis until their livers were severely damaged. This puts "patients at increased risk of medical complications" and contributes to the "transmission of the hepatitis C virus." In an article published in May 2016 in Health Affairs, the authors proposed the authors proposed the invocation of the federal "government patent use" law which would enable the government to procure "important patent-protected" drugs at lower prices while compensating "the patent-holding companies reasonable royalties...for research and development." By July 2017, Louisiana’s health secretary—Rebekah Gee—who described Louisiana as Americas's "public-health-crisis cradle", is investigating the use of the "government patent use" as a strategy.
In Germany negotiations between Gilead and health insurers led to a price of €41,000 for 12 weeks of treatment. This is the same price previously negotiated with the national healthcare system in France, except that additional discounts and rebates apply in France depending on the volume of sales and the number of treatment failures.
In Switzerland the price is fixed by the state every three years. The price is CHF 16,102.50 for 24 pills of 400 mg.
The price in the United Kingdom is expected to be £35,000 (~US$68,110) for 12 weeks. NHS England has established 22 Operational Delivery Networks to roll out delivery which was approved by the National Institute for Health and Care Excellence in 2015 and proposes to fund 10,000 courses of treatment in 2016-17. Each has been given a "run rate" of how many people they are allowed to treat, which was the NHS’ single biggest new treatment investment in 2016.
Unlike Western countries, sofosbuvir is more affordable in Japan and South Korea at approximately $300 and $5900 respectively for a 12-week treatment, with each government covering 99% and 70% of the cost respectively.
In 2014, Gilead announced that it would seek generic licensing agreements with manufacturers to produce sofosbuvir in 91 developing countries, containing 54% of the world's HCV-infected population and that it would sell a name brand version of the product in India for $300 per course of treatment, approximately double a third party estimate of the minimum achievable cost of manufacture. It had signed licenses with generic manufacturers by September 2015. The leader of one Indian activist group called this move inadequate, but nine companies launched products, which "unleashed a fierce marketing war", according to India's The Economic Times.
Jennifer Cohn of Doctors without Borders and the organization Doctors of the World criticized the price of sofosbuvir as reflecting "corporate greed" and ignoring the needs of people in developing countries. In contrast, the Access to Medicines Index ranked Gilead first among the world's 20 largest pharmaceutical countries in the Pricing, Manufacturing and Distribution category in both 2013 and 2014, citing Gilead's "leading performance in equitable pricing".
In Algeria, as of 2011 about 70,000 people were infected with hepatitis C. As of August 2015, Gilead had licensed its partners in India to sell sofosbuvir in Algeria. It had been criticized for not making the drug available in middle-income countries including Algeria prior to that.
In February 2015 it was reported that Doctors of the World had submitted an objection to Gilead's patent at the European Patent Office claiming that the structure of sofosbuvir is based on already known molecules. In particular, Doctors of the World argue that the Protide technology powering sofosbuvir has been previously invented by the McGuigan team at Cardiff University in the UK, and that the Gilead drug is not therefore inventive. The group filed challenges in other developing world countries as well.
Combinations of sofosbuvir with NS5A inhibitors, such as daclatasvir, ledipasvir or velpatasvir, have shown sustained virological response rates of up to 100% in people infected with HCV. Most studies indicate that the efficacy rate is between 94% and 97%; much higher than previous treatment options.
- Tenofovir alafenamide—a nucleotide reverse-transcriptase inhibitor that uses similar phosphoramidate prodrug technology
- "Sofosbuvir". The American Society of Health-System Pharmacists. Retrieved Nov 30, 2016.
- Divya Rajagopal for the Economic Times. Sept 12, 2015. Can Indian generic makers find gold with a blockbuster Hepatitis C drug?
- "Sofosbuvir (Sovaldi) - Treatment - Hepatitis C Online". www.hepatitisc.uw.edu. Retrieved 8 January 2017.
- FDA, News Release (June 28, 2016). "FDA approves Epclusa for treatment of chronic Hepatitis C virus infection".
- "Sovaldi 400 mg film coated tablets - Summary of Product Characteristics (SPC) - (eMC)". www.medicines.org.uk. Retrieved 8 January 2017.
- "Sofosbuvir label" (PDF). FDA. August 2015.
- "Direct-Acting Antivirals for Hepatitis C: Drug Safety Communication - Risk of Hepatitis B Reactivating". FDA. 4 October 2016. Retrieved 6 October 2016.
- "Sovaldi 400 mg film coated tablets - Summary of Product Characteristics". UK Electronic Medicines Compendium. September 2016. Retrieved 10 November 2016.
- Gounder, Celine (9 December 2013). "A Better Treatment for Hepatitis C". The New Yorker.
- "WHO Model List of Essential Medicines (19th List)" (PDF). World Health Organization. April 2015. Retrieved 8 December 2016.
- Hill, A; Simmons, B; Gotham, D; Fortunak, J (1 January 2016). "Rapid reductions in prices for generic sofosbuvir and daclatasvir to treat hepatitis C.". Journal of virus eradication. 2 (1): 28–31. PMC . PMID 27482432.
- Associated Press; Alonso-Zaldivar, Ricardo (July 29, 2014). "Gilead's Sovaldi prescribed more than all other hepatitis C drugs combined – The Mercury News". Mercury News.
- "Recommendations for Testing, Managing, and Treating Hepatitis C" (PDF). AASLD/IDSA. 27 September 2016. Retrieved 10 November 2016.
- "EPCLUSA (sofosbuvir and velpatasvir) Prescribing information" (PDF). Gilead Sciences, Inc. Retrieved 16 June 2017.
- Berden FA, Kievit W, Baak LC, et al. (October 2014). "Dutch guidance for the treatment of chronic hepatitis C virus infection in a new therapeutic era". Neth J Med. 72 (8): 388–400. PMID 25387551.
- Cholongitas E, Papatheodoridis GV (2014). "Sofosbuvir: a novel oral agent for chronic hepatitis C". Ann Gastroenterol. 27 (4): 331–337. PMC . PMID 25332066.
- Tran TT (December 2012). "A review of standard and newer treatment strategies in hepatitis C". Am J Manag Care. 18 (14 Suppl): S340–9. PMID 23327540.
- Yau AH, Yoshida EM (September 2014). "Hepatitis C drugs: the end of the pegylated interferon era and the emergence of all-oral interferon-free antiviral regimens: a concise review". Can J Gastroenterol Hepatol. 28 (8): 445–51. PMC . PMID 25229466.
- Calvaruso V, Mazza M, Almasio PL (May 2011). "Pegylated-interferon-α(2a) in clinical practice: how to manage patients suffering from side effects". Expert Opin Drug Saf. 10 (3): 429–35. PMID 21323500. doi:10.1517/14740338.2011.559161.
- "Copegus (Ribavirin, USP Tablets) Medication Guide" (PDF). Roche. Retrieved 28 October 2014.
- Bhatia, Harmeet Kaur; Singh, Harmanjit; Grewal, Nipunjot; Natt, Navreet Kaur (2014-01-01). "Sofosbuvir: A novel treatment option for chronic hepatitis C infection". Journal of Pharmacology & Pharmacotherapeutics. 5 (4): 278–284. ISSN 0976-500X. PMC . PMID 25422576. doi:10.4103/0976-500X.142464.
- Karageorgopoulos, Drosos E.; El-Sherif, Omar; Bhagani, Sanjay; Khoo, Saye H. (February 2014). "Drug interactions between antiretrovirals and new or emerging direct-acting antivirals in HIV/hepatitis C virus coinfection". Current Opinion in Infectious Diseases. 27 (1): 36–45. PMID 24305043. doi:10.1097/QCO.0000000000000034.
- Pol, Stanislas; Vallet-Pichard, Anaïs; Corouge, Marion (March 2016). "Daclatasvir–sofosbuvir combination therapy with or without ribavirin for hepatitis C virus infection: from the clinical trials to real life". Hepatic Medicine: Evidence and Research. 8: 21–6. PMC . PMID 27019602. doi:10.2147/HMER.S62014.
- Fung, A; Jin, Z; Dyatkina, N; Wang, G; Beigelman, L; Deval, J (2014). "Efficiency of incorporation and chain termination determines the inhibition potency of 2'-modified nucleotide analogs against hepatitis C virus polymerase". Antimicrobial Agents and Chemotherapy. 58 (7): 3636–45. PMC . PMID 24733478. doi:10.1128/AAC.02666-14.
- Ma, H.; Jiang, W.-R.; Robledo, N.; Leveque, V.; Ali, S.; Lara-Jaime, T.; Masjedizadeh, M.; Smith, D. B.; Cammack, N.; Klumpp, K.; Symons, J. (2007). "Characterization of the Metabolic Activation of Hepatitis C Virus Nucleoside Inhibitor β-d-2′-Deoxy-2′-fluoro-2′-C-methylcytidine (PSI-6130) and Identification of a Novel Active 5′-Triphosphate Species". The Journal of Biological Chemistry. 282 (41): 29812–29820. PMID 17698842. doi:10.1074/jbc.M705274200.
- Kirby, Brian J.; Symonds, William T.; Kearney, Brian P.; Mathias, Anita A. (2015-03-31). "Pharmacokinetic, Pharmacodynamic, and Drug-Interaction Profile of the Hepatitis C Virus NS5B Polymerase Inhibitor Sofosbuvir". Clinical Pharmacokinetics. 54 (7): 677–690. PMID 25822283. doi:10.1007/s40262-015-0261-7.
- Dinnendahl, V; Fricke, U, eds. (2015). Arzneistoff-Profile (in German). 9 (28 ed.). Eschborn, Germany: Govi Pharmazeutischer Verlag. ISBN 978-3-7741-9846-3.
- Murakami E, Tolstykh T, Bao H, Niu C, Steuer HM, Bao D, Chang W, Espiritu C, Bansal S, Lam AM, Otto MJ, Sofia MJ, Furman PA (November 2010). "Mechanism of activation of PSI-7851 and its diastereoisomer PSI-7977". J. Biol. Chem. 285 (45): 34337–47. PMC . PMID 20801890. doi:10.1074/jbc.M110.161802.
- "Application Number: 204671Orig1s000: Medical Reviews" (PDF). FDA. November 20, 2013.
- "FDA approves Sovaldi for chronic hepatitis C". FDA New Release. U.S. Food and Drug Administration. 2013-12-06.
- Tucker M (December 6, 2013). "FDA Approves 'Game Changer' Hepatitis C Drug Sofosbuvir". Medscape.
- "FDA approves first combination pill to treat hepatitis C".
- "Hepatitis C Dilemma: Treat Illness With Interferon Now or Wait? - WSJ".
- Herper, Matthew (February 21, 2014). "Gilead's Hepatitis C Pill Takes Off Like A Rocket". Forbes.
- "Essential Medicines WHO Model List, 19th edition, April 2015" (PDF). World Health Organization. 2015.
- Harris, Gardiner (15 September 2014). "Maker of Costly Hepatitis C Drug Sovaldi Strikes Deal on Generics for Poor Countries". The New York Times.
- Boseley, Sarah (15 January 2015). "Hepatitis C drug delayed by NHS due to high cost". The Guardian.
- Stanton, Tracy. "Activists pounce on $1,000-a-day price for Gilead's hep C wonder drug, Sovaldi". FiercePharma. Fierce. Retrieved 22 February 2014.
- Waldman, Ron. "Gilead's HCV drug sofosbuvir approved by the FDA but accessible for how many?" (PDF). Doctors of the World. Retrieved 22 February 2014.
- "C형간염 치료제 건강보험 적용". Retrieved 2 August 2016.
- 무단전재, Ⓒ 종합 경제정보 미디어 이데일리-상업적; 금지, 재배포 (20 April 2016). "C형 간염 치료제 신약, 내달 1일부터 건강보험 적용". Retrieved 2 August 2016.
- van de Ven N, Fortunak J, Simmons B, et al. (December 2014). "Minimum target prices for production of direct acting antivirals and associated diagnostics to combat Hepatitis C Virus". Hepatology. 61 (4): 1174–82. PMC . PMID 25482139. doi:10.1002/hep.27641.
- Kalra, Aditya; Siddiqui, Zeba (September 15, 2014). "Gilead licenses hepatitis C drug to Cipla, Ranbaxy, five others". Reuters India.
- Pollack, Andrew (October 10, 2014). "Harvoni, a Hepatitis C Drug from Gilead, Wins F.D.A. Approval". The New York Times.
- Staff (December 11, 2014). "Gilead Faces Lawsuit Over Hepatitis C Drug Pricing". Drug Discovery & Development. United States: Advantage Business Media. Associated Press.
- Pollack, Andrew (December 6, 2013). "F. D. A. Approves Pill to Treat Hepatitis". The New York Times.
- Armstrong, Drew (21 March 2014). "Gilead's $84,000 Treatment Questioned by U.S. Lawmakers". Bloomberg. Retrieved 27 October 2015.
- Lucio, Steven (February 2015). "The Increasing Impact of High-Cost Specialty Therapies". Pharmacy Purchasing & Products Magazine. Retrieved 4 December 2015.
- Brennan, T.; Shrank W. (2014). "New expensive treatments for hepatitis C infection". JAMA. pp. 593–594.
- "Gilead Q4 2014 Earnings Call".
- "New Lower Prices for Gilead Hepatitis C Drugs Reach CTAF Threshold for High Health System Value" (Press release). 2015-02-17. Retrieved 2015-02-22.
- California Technology Assessment Forum (2014-03-10). "Treatments for Hepatitis C".
- "Medical Groups Question Price of New Hep C Drug". The New York Times. Associated Press. 11 March 2014.
- Johnson, Carolyn Y. (July 3, 2017). "Louisiana considers radical step to counter high drug prices: Federal intervention". Baton Rouge, Louisiana. Retrieved July 4, 2017.
- Kapczynski, Amy; Kesselheim, Aaron S. (May 10, 2016). "'Government Patent Use': A Legal Approach To Reducing Drug Spending" (PDF). Health Affairs. 35 (5791-797). doi:10.1377/hlthaff.2015.1120. Retrieved June 4, 2017.
- "Gilead strikes Sovaldi price deal in Germany as it picks up speed in EU".
- "Sovaldi / Sofosbuvir medication in Switzerland".
- "NHS England rollout of ground-breaking drugs 'changes role of NICE'". Health Service Journal. 4 April 2016. Retrieved 14 May 2016.
- "Pricing, Manufacturing & Distribution | Access to Medicine Index 2014".
- amfAR Feb. 2015 Hepatitis C and Drug Pricing: The Need for a Better Balance
- Drugs for Neglected Diseases Initiative April 2016 An Alternative Research and Development Strategy to Deliver Affordable Treatments for Hepatitis C Patients
- Gilead. August 2015. Chronic Hepatitis C Treatment Expansion Generic Manufacturing for Developing Countries
- Doctors without Borders. May, 2015 Strategies to Secure Access to Generic Hepatitis C Medicines
- Nicola Kuhrt (February 10, 2015). "Hepatitis-Pille Sovaldi: "Ärzte der Welt" geht gegen Patent vor" (in German). Der Spiegel. Retrieved February 10, 2015.
- Einhorn, Bruce. "How India's Patent Office Destroyed Gilead's Global Game Plan". Bloomberg.com. Retrieved 2015-12-30.
- Michael Mezher for Regulatory Affairs Professionals Society. February 4, 2015 Follow the Rules, Indian Court Tells Patent Office in Sovaldi Case
- Jyothi Datta for the Hindu Business Line. February 2, 2015 More patent-opposition on Gilead's hepatitis C drug, sofosbuvir
- "DOCTORS OF THE WORLD—MÉDECINS DU MONDE OPPOSES SOFOSBUVIR PATENT IN EUROPE". Médecins du Monde. Retrieved 12 February 2015.
- "European Patent EP2203462, granted 21 May 2014". European Patent Register. European Patent Office. Retrieved 12 February 2015.
- "Conflit autour d’un traitement contre l’hépatite C" (in French). February 10, 2015. Retrieved March 4, 2015.
- "Charity challenges Gilead's European patent on hepatitis C therapy Sovaldi". February 10, 2015. Retrieved March 4, 2015.
- "High Cost of Sovaldi Hepatitis C Drug Prompts a Call to Void Its Patents - The New York Times".
- Childs-Kean, Lindsey (January 16, 2015). "Simeprevir and Sofosbuvir for Treatment of Chronic Hepatitis C Infection". Clinical Therapeutics. 37 (2): 243–67. PMID 25601269. doi:10.1016/j.clinthera.2014.12.012.
- Smith, Michael (December 16, 2014). "Interferon-/Ribavirin-Free Regimen for Chronic Hepatitis C Virus Infection". Annals of Pharmacotherapy. 49 (3): 343–50. PMID 25515863. doi:10.1177/1060028014563952.
- "Comparison of tenofovir prodrugs: TAF vs TDF". DRUG R&D INSIGHT. Retrieved 24 November 2015.
- Murakami, E.; Tolstykh, T.; Bao, H.; Niu, C.; Steuer, H. M. M.; Bao, D.; Chang, W.; Espiritu, C.; Bansal, S.; Lam, A. M.; Otto, M. J.; Sofia, M. J.; Furman, P. A. (26 August 2010). "Mechanism of Activation of PSI-7851 and Its Diastereoisomer PSI-7977". Journal of Biological Chemistry. 285 (45): 34337–34347. PMC . PMID 20801890. doi:10.1074/jbc.M110.161802.